Skip to main content

Table 1 Patients and tumour characteristics

From: MMP-1 expression has an independent prognostic value in breast cancer

Variable Number of patients (%)
Number of the patients 125 (aged 30-90, mean 57, 5)
Grade  
   I 10 (8%)
   II 66 (52, 8%)
   III 49 (39, 2%)
Axillary nodal status  
   N0 64 (51, 2%)
   ≥N1 50 (40%)
   Unknown 11 (8, 8%)
Estrogen receptor status (ER) 1)  
   Positive 80 (64%)
   Negative 45 (36%)
Progesterone receptor status (PR) 1)  
   Positive 82 (65, 6%)
   Negative 43 (34, 4%)
Ki-67 status 2)  
   low ≤ 15% 63 (50,4%)
   intermediate 16-30% 41 (32,8%)
   high > 30% 20 (16%)
   one value missing 1 (8%)
Histologic type  
   Ductal 110 (88%)
   Lobular 10 (8%)
   Subtypes 5 (4%)
Her2 3)  
   IHC positive (2+ and 3+) 25 (20%)
   IHC negative (0 and 1+) 100 (80%)
CK 5/6 4)  
   Triple-negative (ER-, PR-, Her2-) 35 (28%)
   Basal-like carcinoma (ER-, PR-, Her2-, CK5/6+) 20 (16%)
Treatment after operation  
   Chemotherapy 27 (21,6%)
   Radiation 59 (47,2%)
   Hormonal therapy 24 (19,2%)
  1. 1,4) Cut off point used for ER and PR immunohistochemistry is 10% of positively stained tumour nuclei and 10% cytoplasmic staining for CK5/6.
  2. 2) Proliferation index according to St Gallen Consesus (Goldhirsch et al 2009).
  3. 3) Scoring of HER2 immunohistochemistry: Score 0: no staining is observed or cell membrane staining is observed in less than 10% of tumour cells. Score 1+: a faint perceptible membrane staining can be detected in more than 10% of the tumour cells or cells are only stained in part of their membrane. Score 2+: a weak to moderate complete membrane staining is observed in more than 10% of the tumour cells. Score 3+: a strong complete membrane staining is observed in more than 10% of the tumour cells.